Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Neurotech InternationalNTILF 34 EV-to-EBITDA is -1.15 as of Jul. 30, 2026. GuruFocus rates NTILF with a GF Score™ of 34/100. The stock has 1 warning sign investors should review. Among 407 Biotechnology companies, Neurotech International ranks worse than 245700% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Neurotech International's enterprise value is $8.39 Mil.
Neurotech International's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $-7.27 Mil. Therefore, Neurotech International's EV-to-EBITDA for today is -1.15.
The historical rank and industry rank for Neurotech International's EV-to-EBITDA or its related term are showing as below:
NTILF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -15.35 Med: -3.81 Max: 0.46
Current: -1.46
During the past 9 years, the highest EV-to-EBITDA of Neurotech International was 0.46. The lowest was -15.35. And the median was -3.81.
NTILF's EV-to-EBITDA is ranked worse than 100% of 407
companies
in the Biotechnology industry
Industry Median: 11.7
vs NTILF: -1.46
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Neurotech International (OTCPK:NTILF) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Neurotech International's PE Ratio (TTM) for today is calculated as:
Neurotech International's share price for today is $0.001.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Neurotech International's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.002.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NTILF vs VRTX, REGN, RVMD: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Neurotech International's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Neurotech International EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Neurotech International's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Neurotech International's EV-to-EBITDA falls into.
Neurotech International's current Enterprise Value is $8.39 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Neurotech International's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $-7.27 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Neurotech International (NTILF) has a EV-to-EBITDA of -1.15 as of Jul. 30, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Neurotech International. According to the industry distribution chart, Neurotech International ranks #999999 out of 407 companies in the Biotechnology industry.
Is Neurotech International's EV-to-EBITDA too high?
Neurotech International's current EV-to-EBITDA is -1.15. Based on the distribution chart, Neurotech International ranks #999999 out of 407 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Neurotech International has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Neurotech International's EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Neurotech International ranks #999999 out of 407 companies for EV-to-EBITDA. This places Neurotech International in the lower half of its industry. The industry median EV-to-EBITDA is 11.70. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 11.70, based on 407 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Neurotech International. For the Biotechnology industry, the median EV-to-EBITDA is 11.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Neurotech International's current EV-to-EBITDA is -1.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neurotech International stock overvalued right now?
Neurotech International (NTILF) has a current EV-to-EBITDA of -1.15. The current EV-to-EBITDA is -1.15. Neurotech International's overall GF Score™ is 34/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Neurotech International (NTILF), the current EV-to-EBITDA is -1.15 as of Jul. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Neurotech International Ltd is a clinical-stage biopharmaceutical development company. It is focused predominantly on paediatric neurological disorders with a broad-spectrum oral cannabinoid drug therapy called NTI164. NTI164 is a proprietary broad-spectrum cannabinoid drug candidate with a safety and efficacy profile across several paediatric neurological conditions with high unmet need. The group is working across various clinical programs, which include Autism Spectrum Disorder (ASD), Rett Syndrome, PANDAS/PANS, and Human Pharmacokinetics. It is conducting clinical studies to assess the neuro-protective, anti-inflammatory, and neuro-modulatory activities of its proprietary NTI/Dolce cannabis strains.
34GF Score
Get the complete analysis for NTILF
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NTILF has been successfully added to your 
